文献速递青光眼

VEGF-C与5-氟尿嘧啶联合使用改善兔青光眼手术小梁切除术模型中的滤过泡存活

VEGF-C and 5-Fluorouracil Improve Bleb Survival in a Rabbit Glaucoma Surgery Trabeculectomy Model.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

研究在32只兔青光眼滤过手术模型中评估VEGF-C诱导的淋巴增殖联合5-氟尿嘧啶(5-FU)抗代谢治疗的效果。VEGF-C联合5-FU组的滤过泡在向后延伸长度和宽度上均大于其他各组,且滤过泡存活时间更长,仅该组眼压与时间呈显著负相关。结论认为在标准抗代谢治疗中加入VEGF-C淋巴增殖可改善兔滤过手术成功率,可能提示未来改善人类滤过手术的策略。

要点

  • VEGF-C联合5-FU组滤过泡向后更长更宽,优于5-FU、VEGF-C及对照组。
  • 30天后VEGF-C联合5-FU组滤过泡存活时间较其他三组更长。
  • 仅VEGF-C联合5-FU组眼压与时间呈显著负相关(r=-0.533,P=0.034)。

核心结论

  • 在标准抗代谢治疗中加入VEGF-C淋巴增殖可改善兔青光眼滤过手术的成功率,可能提示未来改善人类滤过手术的策略。

研究设计与样本

  • 32只兔接受青光眼滤过手术,按结膜下药物治疗分为四组(每组n=8):VEGF-C联合5-FU组、5-FU组、VEGF-C组和对照组。
  • 评估滤过泡存活、滤过泡测量和眼压共30天,结束时对部分眼行组织学检查和前节OCT,其余眼提取mRNA行RT-PCR检测血管特异性标志物。

主要发现

  • VEGF-C联合5-FU组滤过泡向后长度和宽度均大于其他条件:对比5-FU组长度P=0.043、宽度P=0.046,对比VEGF-C组P<0.001、P<0.001,对比对照组P<0.001、P<0.001。
  • 30天后VEGF-C联合5-FU组滤过泡存活时间较5-FU组更长(P=0.025),较VEGF-C组更长(P<0.001),较对照组更长(P<0.001)。
  • 仅VEGF-C联合5-FU组眼压与时间呈统计学显著负相关(r=-0.533;P=0.034)。
  • 前节OCT和组织学显示VEGF-C联合5-FU组滤过泡更大。
  • 仅含VEGF-C的条件导致淋巴标志物表达增加(LYVE-1,P<0.001-0.008;podoplanin,P=0.002-0.011),CD31表达组间无差异(P=0.978)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate VEGF-C-induced lymphoproliferation in conjunction with 5-fluorouracil (5-FU) antimetabolite treatment in a rabbit glaucoma filtration surgery (GFS) model. METHODS: Thirty-two rabbits underwent GFS and were assigned to four groups (n = 8 each) defined by subconjunctival drug treatment: (a) VEGF-C combined with 5-FU, (b) 5-FU, (c) VEGF-C, (d) and control. Bleb survival, bleb measurements, and IOP were evaluated over 30 days. At the end, histology and anterior segment OCT were performed on some eyes. mRNA was isolated from the remaining eyes for RT-PCR evaluation of vessel-specific markers (lymphatics, podoplanin and LYVE-1; and blood vessels, CD31). RESULTS: Qualitatively and quantitatively, VEGF-C combined with 5-FU resulted in blebs which were posteriorly longer and wider than the other conditions: vs. 5-FU (P = 0.043 for longer, P = 0.046 for wider), vs. VEGF-C (P < 0.001, P < 0.001) and vs. control (P < 0.001, P < 0.001). After 30 days, the VEGF-C combined with 5-FU condition resulted in longer bleb survival compared with 5-FU (P = 0.025), VEGF-C (P < 0.001), and control (P < 0.001). Only the VEGF-C combined with 5-FU condition showed a negative correlation between IOP and time that was statistically significant (r = -0.533; P = 0.034). Anterior segment OCT and histology demonstrated larger blebs for the VEGF-C combined with 5-FU condition. Only conditions including VEGF-C led to increased expression of lymphatic markers (LYVE-1, P < 0.001-0.008 and podoplanin, P = 0.002-0.011). Expression of CD31 was not different between the groups (P = 0.978). CONCLUSIONS: Adding VEGF-C lymphoproliferation to standard antimetabolite treatment improved rabbit GFS success and may suggest a future strategy to improve human GFSs.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Wu J, Zhou L, Liu Y, et al. VEGF-C and 5-Fluorouracil Improve Bleb Survival in a Rabbit Glaucoma Surgery Trabeculectomy Model. Invest Ophthalmol Vis Sci. 2024. PMID: 38771570. doi:10.1167/iovs.65.5.32

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。